Takeda’s Entyvio Faces PML Hurdle At Advisory Committee, Thanks To Tysabri
This article was originally published in The Pink Sheet Daily
Executive Summary
Entyvio’s clinical trials found no cases of progressive multifocal leukoencephalopathy, but FDA remains concerned because the product’s mechanism of action is similar to Tysabri, which is associated with PML.